an important mechanism in the development and progression of several diseases. 9 Yet, the role of miRs in atherosclerosis has not been fully elucidated. Recently, miR33a/b have been shown to act as post-transcriptional regulators of lipid metabolism, and their pharmacological inhibition diminished atherosclerosis by raising plasma high-density lipoprotein-cholesterol and lowering very-low-density lipoprotein triglycerides levels. 10 Also, in vitro data indicate that the endothelial expression of miRs is regulated by SS [11] [12] [13] [14] [15] [16] and can modulate endothelial inflammation, 11, [17] [18] [19] suggesting that these miRs might play a role in atherosclerosis. 20 However, to date there exists no direct in vivo evidence to support the involvement of SS-regulated miRs in the development of atherosclerosis. Here, we hypothesized that SS might control the inflammatory response of endothelial cells to oxLDL through the expression of a limited set of specific miRs, that we named atheromiRs. By using a large-scale microarray analysis of miR expression in endothelial cells exposed to low or high SS in the presence or absence of oxLDL, we identify miR-92a as an atheromiR candidate, and Suppressor of Cytokine Signaling 5 (SOCS5) as a novel miR-92a target. The present study shows that antagomiR-92a treatment prevents endothelial dysfunction and limits the development of atherosclerotic lesions in Ldlr −/− mice, therefore establishing a major in vivo role for miR-92a in the inflammatory endothelial dysfunction leading to atherosclerosis.
Methods

Cell Culture
Confluent human umbilical vein endothelial cells (HUVECs; passage 2-4; Promocell, Heidelberg, Germany) were cultured on 0.2% gelatin-coated slides (Menzel Glazer; Braunschweig, Germany) in endothelium cell basal medium containing growth factors, 1% fetal calf serum (Promocell), streptomycin (100 IU/mL), penicillin (100 IU/ mL), and Amphotericin B (10 μg/L). Human vascular smooth muscle cells (hVSMCs; ATCC, passage 2-5) were cultured in smooth muscle medium (Promocell) and macrophages in RMPI1640 Gutamax medium (Gibco). To activate macrophages, stimulation with IFNγ (100 U/mL, BD) and lipopolysaccharide (1 μg/μL Sigma-Aldrich) was performed for 24 hours.
Shear Stress Experiments
A controlled level of laminar SS was applied to confluent HUVECs using a parallel plate chamber connected to a perfusion system driven by a peristaltic pump (Gilson) as previously described in the work by Ramkhelawon et al. 21 The flow chamber was placed in a sterile 5% CO 2 incubator set at 37°C. HUVECs were placed in the perfusion system for 24 hours and exposed either to low SS (low SS, 4 dyn/cm 2 ) or high SS (high SS, 15 dyn/cm 2 ). To mimic atheroprone conditions, HUVECs were exposed to proatherogenic oxLDL (25 μg/ mL; Biomedical Technologies). Degree of LDL oxidation was given by manufacturer and determined by thiobarbituric acid reactive substance content analysis using malondialdhyde quantification (26.9 nmoles/mg proteins). Native LDL (Biomedical Technologies) were treated with 40 μmol/L 3,5-Di-tert-4 butylhydroxytoluene (BHT, Sigma-Aldrich) and 0.25 mmol/L ethylenediaminetetraacetic acid to prevent oxidation.
miRNA Expression Analysis
Total RNAs were prepared using Trizol (Invitrogen). miRNA profiling was realized in Millteny. miRNA expression was determined using Taqman miRNA assay (Life Technologies) according to manufacturer protocols. U6 snRNA was used as endogenous control.
In Vivo miR-92a Inhibition in Ldlr −/−
All experiments were performed in accordance with the European Community Guidelines for the care and use of laboratory animals (No.07430). Eight-week-old male Ldlr −/− mice (Charles River) were fed a high-fat diet for 14 weeks. AntagomiR treatment started at week 4. We tested 2 AntagomiRs doses (8 and 16 mg/kg), and we found the 16 mg/kg dose to be more efficient. AntagomiRs (VBC biotech, Vienna) were delivered by retro-orbital i.v. injections under brief anesthesia. A second injection was performed at week 9. A scramble antagomiR (Antagomir-Control) was used as control. AntagomiRControl (anti-Ctrl): 5′-AAGGCAAGCUGACCCUGAAGUU-3′ and antagomiR-92a (anti-92a): 5′-CAGGCCGGGACAAGUGCAAUA-3′. PBS-treated mice were used as control of the scramble antagomiR. The study design is shown in Online Figure VIII.
SOCS5 3′ Untranslated Region Luciferase Assay
For validation of SOCS5 as a target of miR-92a, 3′ untranslated region of human SOCS5 was cloned into a mammalian expression vector with dual luciferase reporter system (GeneCopoeia). Human embryonic kidney 293 cells were transfected using Hiperfect (Qiagen). Transfections were performed using 1 μg dual luciferase reporter plasmids and a final concentration of 100 nmol/L synthetic miR-92a mimic, or miR-21 as an irrelevant miRNA mimic (Applied Biosystems). Twenty-four hours after transfection, dual luciferase assays were performed using LucPair miR luciferase assay kit (GeneCopoeia) according to manufacturer instructions. Firefly luciferase activity was normalized to Renilla luciferase expression control. The QuikChange II XL site-directed mutagenesis kit (Agilent) was used to mutate miR-92a binding site at SOCS5 3′ untranslated region.
STAT3 Inhibition In Vitro and In Vivo
Cell cultures were preincubated with Stattic (2 μM/L; Calbiochem), a nonpeptitic specific signal transducer and activator of transcription 3 (STAT3) inhibitor, for 1 hour and then subjected to SS and oxLDL stimulation in the presence of Stattic for 24 hours. In vivo STAT3 inhibition was performed in Ldlr −/− mice as previously described.
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Statistical Analysis
Data are mean±SEM unless otherwise stated. Statistical analysis was performed with the GraphPad software. For statistical comparison, we used ANOVA followed by Bonferroni post hoc test or otherwise stated in figure legends. Differences were considered significant when P<0.05. For detailed experimental methods, please refer to the Online Data Supplement.
Results
Endothelial miR-92a Expression Is Differentially Regulated by Shear Stress and Hypercholesterolemia
HUVECs were subjected to either low SS or high SS in the presence or absence of oxLDL for 24 hours. RNAs were then isolated and miRNAs expression profiled. Data were expressed as delta (∆) log2 values (Online Tables I and II) . We defined atheromiRs as miRs fulfilling the following 2 criteria: (1) expression is changed by oxLDL under low SS, and (2) expression is not or barely affected by oxLDL under high SS (Online Table  II ). As shown in Figure 1A (right panel), we identified miR92a as the most dysregulated microRNA. the microarray data by qPCR ( Figure 1B) . First, miR-92a expression was higher in HUVECs exposed to atheroprone low SS as compared with atheroprotective high SS. Second, oxLDL stimulation significantly increased miR-92a expression in low SS conditions but had no effect on cells exposed to high SS. The observed modulations were specific of oxLDL but for native LDL stimulation had no effect (Online Figure I) . Because miR-92a is part of the miR-17 to 92 cluster, we next quantified the expression of this cluster to determine whether other orthologs could fulfill the atheromiR criteria (Online Figure II) . Interestingly, only miR-92a fulfilled these criteria. To confirm our findings in vivo, we investigated the relative expression of miR-92a in atheroprone (aortic arch) versus protected (descending thoracic aorta) regions of aorta in normocholesterolemic Ldlr +/+ and hypercholesterolemic Ldlr −/− mice. In normocholesterolemic C57Bl/6 mice, miR-92a expression was higher in the aortic arch as compared with the descending aorta ( Figure 1C ). Interestingly, we observed a significant increase of miR-92a expression in the aortic arch of Ldlr −/− mice compared with normocholesterolemic animals, whereas its expression remained unchanged in the descending aorta ( Figure 1C ). In agreement with our in vitro findings, miR-92a was the only miR within the miR-17 to 92 cluster to exhibit the atheromiR characteristics in vivo (Online Figure III) . We also addressed the relevance of these findings to human atherosclerosis. We found that miR-92a was highly expressed in the downstream parts of human carotid plaques where low SS prevails 23, 24 as compared with the upstream parts, where its expression was similar to healthy parts of carotid arteries ( Figure 1D ).
The endothelial specificity of miR-92a was further confirmed by comparing its expression in endothelial cells, vascular smooth muscle cells, and macrophages on oxLDL or lipopolysaccharide/IFNγ stimulation. Indeed, miR-92a expression was ≈15-fold higher in endothelial cells than in vascular smooth muscle cells or macrophages (Online Figure IV) . Although macrophage expression of miR-92a was low, we assessed its potential role on foam cell formation by studying the effect of its overexpression or inhibition on oxLDL uptake in macrophages. We observed no effect of the modulation of miR-92a expression on lipid accumulation by macrophages (Online Figure V) .
Moreover, in situ hybridization in mice showed that miR-92a expression was confined to the endothelium (Online Figure VI) and showed stronger expression in the inner curvature where low and oscillatory SS prevail compared with the outer curvature (Online Figure VI) . Additionally, the pattern of miR-92a staining was similar to CD31 staining, indicating a preferential localization to endothelial cells.
In Vitro miR-92a Inhibition Protects Against Endothelial Inflammation in Response to Low Shear Stress and oxLDL Stimulation, and Prevents Monocyte Adhesion
To investigate the effects of miR-92a on endothelial inflammatory responses, we quantified IL-6 and MCP-1 release by ELISA after HUVEC transfection with specific miR-92a modulators (antimiR-92a or premiR-92a). AntimiR-92a efficiently blocked endothelial miR-92a expression under low and high SS in the presence or absence of oxLDL. PremiR-92a enhanced miR-92a expression in cells exposed to low SS but was much less efficient in cells under high SS likely because of potent counter-regulatory mechanisms exerted by SS. Additionally, miR-92a modulation did not affect ortholog expression in response to SS and oxLDL (Online Figure VII) . PremiR-92a similarly increased IL-6 and MCP-1 secretion, whereas miR-92a inhibition reduced it (Figure 2 ). We verified that the transfection itself had no effect on cytokine release (Online Table III) .
OxLDL stimulation specifically increased IL-6 and MCP-1 secretion under low SS, which was partly reversed after miR-92a inhibition (Figure 2A and 2C) . In contrast, miR-92a overexpression increased IL-6 and MCP-1 secretion in response to oxLDL, mainly under low SS ( Figure 2B and 2D) . These findings clearly indicate that miR-92a mediates endothelial cell activation by oxLDL, specifically when SS is low.
To analyze the functional consequences of miR-92a-mediated effects on endothelial activation, we performed a leukocyte-endothelial cell adhesion assay. As expected, adhesion of U937 to endothelial cells was higher under low than under high SS conditions ( Figure 3A and 3C). miR-92a inhibition markedly decreased U937 adhesion under low SS in the presence or absence of oxLDL ( Figure 3A ). In contrast, miR-92a overexpression abrogated the protective effect of high SS and led to a significant increase of U937 adhesion under these conditions ( Figure 3B ).
To further investigate the link between monocyte adhesion and endothelial activation, we determined intercellular adhesion molecule-1 (ICAM-1) expression after miR-92a modulation. As shown in Figure 3C and 3D, ICAM-1 expression was much higher in low than in high SS conditions. oxLDL stimulation increased ICAM-1 expression both in low and high SS conditions. miR-92a inhibition reduced ICAM-1 expression when cells were exposed to low SS both in the presence or absence of oxLDL. Conversely, miR-92a overexpression induced a significant increase of ICAM-1 expression.
Our findings demonstrate that endothelial miR-92a controls oxLDL-induced endothelial cell adhesive properties in an SS-dependent manner.
In Vivo Inhibition of miR-92a Limits the Development of Atherosclerosis
To determine the in vivo role of miR-92a in the setting of progressing atherosclerosis, we specifically blocked miR-92a expression in Ldlr −/− mice fed a high-fat diet. Mice were fed for 4 weeks to initiate the development of atherosclerosis before starting the antagomiR treatment for 10 additional weeks (Online Figure VIII) . A scramble antagomiR (Antagomir-Control) or PBS were used as controls. The efficacy of miR-92a inhibition was assessed in several tissues at the dose of 16 mg/kg, which was slightly more efficient than 8 mg/kg (Online Figure VIII) without affecting ortholog expression. miR-92a was significantly reduced up to 14 weeks after antagomiR treatment in lungs, heart, liver, kidneys, and plasma (Online Figure IX) . It is noteworthy that miR-92a plasma levels in antimiR-92a-treated Ldlr −/− mice were similar to those in C57Bl6 mice (1.01±0.07 Arbitrary Unit). AntagomiR treatment had no effect on body or liver weight, and did not alter the immune profile in blood and spleen (Online Table IV and Online Figure X) . Plasma total cholesterol, high-density lipoprotein-cholesterol, and triglycerides levels were not altered by the antimiR-92a treatment (Online Table IV ).
Quantification of atherosclerotic lesions in the thoracic aorta by en face analysis after 14 weeks of high fat diet showed that antimiR-92a treatment significantly decreased atherosclerosis by 32% compared with anti-Ctrl treatment or PBS ( Figure 4A ). When atherosclerotic lesions were analyzed according to their localization (aortic arch versus thoracic aorta), we found that antagomiR-92a treatment significantly reduced lesions at aortic arch but much less in the thoracic aorta (Online Figure XI) . Aortic sinus lesions also significantly decreased by 23% in antimiR-92a-treated Ldlr −/− mice compared with anti-Ctrl-treated or PBS-treated mice ( Figure 4B ) despite persistent high levels of plasma cholesterol.
Plaque composition analysis was determined by quantification of macrophage, lymphocyte, collagen content, and ICAM-1 expression. As shown in Figure 5 , macrophage and T lymphocyte accumulation were significantly decreased by antimiR-92a treatment compared with PBS-treated or anti-Ctrl-treated mice. In contrast, the collagen content was increased, suggesting that antimiR-92a treatment led to more stable plaques ( Figure 5C ). We also investigated ICAM-1 expression, as a marker of endothelial inflammation, and found that ICAM-1 was markedly decreased by antimiR-92a treatment ( Figure 5D ).
miR-92a Targets In Vitro
Previous studies have shown that miR-92a negatively regulated the key endothelial transcription factors KLF2 and KLF4 through miR-92a recognition elements. 16, 18 Here, we investigated the effect of miR-92a on the expression of KLF2 and KLF4 in endothelial cells in response to flow and oxLDL stimulation. As shown in Online Figure XII, KLF2 and KLF4 expression levels were enhanced under high compared with low SS, both in the presence or absence of oxLDL. Under low SS, both KLF2 and KLF4 were decreased after stimulation with oxLDL. Specific blockade of miR-92a abrogated oxLDL effect and resulted in increased KLF2 and KLF4 expression. Blockade of miR-92a also markedly increased KLF2 and KLF4 expression under high SS. Next, we explored the regulation of NOS3 and NFκB, downstream of KLF2 and KLF4. 25 As shown in Online Figure XII , NOS3 expression was much higher in high compared with low SS. miR-92a inhibition increased NOS3 expression independently of the SS level. The active form of NFκB, phospho-p65, was mainly expressed under low SS compared with high SS. miR-92a inhibition under low SS reduced phospho-p65 expression. Under high SS, blockade of miR-92a resulted in a moderate increase of phospho-p65 that was not affected by oxLDL. p65 expression was consistently more expressed under low SS compared with high SS and was modulated in parallel of KLF2 and KLF4 (Online Figure XIII) . These findings confirm that KLF2 and KLF4 are targeted by miR-92a and show, for the first time, that KLF2 and KLF4 and their downstream elements can be modulated by miR-92a treatment after flow and oxLDL stimulation.
miR-92a Targets In Vivo
To translate our in vitro findings to the in vivo situation, the expression levels of KLF2, KLF4, NOS3, and p65 were determined in aortas of Ldlr −/− mice treated with PBS, anti-Ctrl, or antimiR-92a. As shown in Figure 6 , KLF2 and KLF4 expressions were markedly increased by antimiR-92a treatment compared with PBS and anti-Ctrl treatment. NOS3 expression was increased by antimiR-92a treatment, whereas phospho-p65 expression was decreased. p65 was also decreased by antimiR-92a treatment (Online Figure XIII) .
To further assess the protective effect of antimiR-92a treatment against atherosclerosis-induced endothelial dysfunction, we determined plasma levels of endothelial microparticles (MPs) as a biomarker of endothelial dysfunction. 26 As shown in Figure 6C , circulating endothelial CD144+ MPs levels were increased ≈3-fold in Ldlr −/− mice treated with PBS or anti-Ctrl as compared with age-matched C57BL/6 mice. Interestingly, antimiR-92a treatment prevented endothelial dysfunction in Ldlr −/− mice as shown by the reduction of circulating CD144+ MPs to the level observed in normocholesterolemic mice. We also addressed the inflammatory status of treated mice by quantifying levels of circulating ICAM-1 as a marker of endothelial inflammation. 27 As shown in Figure 6D , circulating ICAM-1 levels were decreased by 31% in mice treated with antimiR-92a as compared with those treated with PBS or anti-Ctrl, indicating that blocking miR-92a protects from endothelial inflammation.
Identification of SOCS5 as a New Target of miR-92a in Response to Shear Stress
Large gene analysis in experimental conditions where miR-92a is highly expressed (low SS+oxLDL+anti-Ctrl) compared with conditions where miR-92a is blocked (low SS+oxLDL+antimiR-92a) allowed us to determine potential new targets (Online Figure XIV) . By using Gene Expression Arrays analysis, we identified 1 gene that was predicted to be a miR-92a target in human and mouse genomes, and was upregulated >25% in low SS+oxLDL+Anti-92a conditions compared with low SS+oxLDL+anti-Ctrl (Online Figure  XIV) . We found that SOCS5 expression was significantly increased and was validated by qPCR (Online Figure XV) . 3′ untranslated region luciferase assay confirmed that miR-92a targeted SOCS5 as shown in Figure 7A . Protein expression level analysis of SOCS5 revealed that SOCS5 was expressed more strongly in high SS than in low SS in vitro. In response to oxLDL, SOCS5 decreased under low SS, whereas no change was observed under high SS. miR-92a inhibition increased, whereas miR-92a overexpression reduced SOCS5 expression in low SS (Figure 7B and 7C) . Modulation of miR92a had no effects in high SS conditions. SOCS5 function was assessed under high SS conditions where its expression was particularly high. We selectively blocked SOCS5 expression using siRNA (Online Figure XVI) . SOCS5 inhibition on high SS and oxLDL stimulation increased IL-6 and MCP-1 release, indicating that SOCS5 protects against inflammation ( Figure 7D and 7E) . Silencing SOCS5 did not affect KLF2, KLF4, and NOS3 expression (Online Figure XVI) .
In vivo, SOCS5 expression was similarly high in the aortic arch and descending aorta of normocholesterolemic mice but markedly decreased in the aortic arch of hypercholesterolemic mice ( Figure 7F ) where expression of miR-92a was the highest and remained highly expressed in the descending aorta of hypercholesterolemic mice where miR-92a was low. We also addressed the relevance of these findings to human atherosclerosis and found that SOCS5 gene expression was highly repressed in the downstream parts of human carotid plaques where low SS prevails 23, 24 and where miR-92a is highly expressed as compared with the upstream parts (Online Figure XVII) .
miR-92a Expression Is Regulated by Stat3 in Atheroprone Conditions
Previous studies have shown that miR-92a expression was driven by several transcription factors (TFs), including STAT3 and c-Myc. 28 On the contrary, these TFs may be regulated by SS. [29] [30] [31] [32] Therefore, we analyzed the expression of these TFs as a function of SS and hypercholesterolemia in vitro and in vivo. We found that STAT3 mRNA expression displayed the same expression pattern as miR-92a both in vitro and in vivo ( Figure 8A and 8B) whereas c-Myc and miR-92a showed different expression patterns (data not shown). To examine the direct effect of STAT3 activation on miR-92a expression, we selectively blocked STAT3 activity using Stattic (see Methods) and found reduced miR-92a expression in response to low SS+oxLDL ( Figure 8C ). Moreover, in vivo blockade of STAT3 in Ldlr −/− mice prevented miR-92a expression in atheroprone areas ( Figure 8D ) and resulted in increased expression of SOCS5 (Online Figure XVIII) . Altogether, these findings highlight the role of STAT3 in the regulation of miR-92a expression in response to SS and hypercholesterolemia and its consequences on endothelial inflammation.
Discussion
The results presented herein demonstrate for the first time the involvement of microRNA-92a in the development of atherosclerosis in vivo. The antagomiR-92a also represents a new strategy to treat atherosclerosis by preventing endothelial dysfunction in hypercholesterolemic state.
The newly emerging gene regulators, miRNAs, have been involved in a wide range of processes, which are linked to atherosclerosis 33 and cardiovascular diseases. 9 We hypothesized that a restricted pool of endothelial miRNAs could be involved in the specific regulation of genes contributing to the development of atherosclerosis. These miRNAs, so-called atheromiRs, could represent targets for the development of new therapeutic strategies against atherosclerosis. Here, we provide strong evidence that miR-92a is an atheromiR, being preferentially expressed in endothelial cells and strongly stimulated by proatherogenic oxLDL, specifically in atheroprone areas where SS is low.
Endothelial activation is a primary event in the development of atherosclerosis lesions. 34 We demonstrated using both loss-and gain-of-function strategies that miR-92a acts as a proinflammatory regulator in endothelial cells by activating inflammatory cytokines and chemokines, and promoting monocyte adhesion. Moreover, NOS3 expression was restored by miR-92a inhibition in vitro. Our findings clearly indicate that miR-92a inhibition prevents in vitro endothelial activation. Additionally, measurement of endothelial MPs, a marker of endothelial dysfunction, 26, 35 and analysis of ICAM-1 expression in lesions demonstrated that antimiR-92a treatment protects against endothelial activation and dysfunction in vivo. Atherosclerosis development is tightly controlled by both innate and adaptive immunity. 36 Although miR-92a expression had been previously reported in T lymphocytes, 37 we did not observe any effect of miR-92a inhibition on immune parameters, including monocyte, T, and B cell counts as well as immune cell activation. These observations reinforce our conclusion that the antiatherogenic effects observed after miR-92a blockade resulted from protection against endothelial dysfunction. However, T cell and macrophage contents in plaques were reduced by antimiR-92a treatment. This was likely because of the antiadhesive effect of miR-92a blockade in endothelial cells, possibly involving KLF2. 38 Previous studies showed that the key endothelial transcription factors, KLF2 and KLF4, are direct targets of miR-92a. 16, 17 Our data indicate that miR-92a inhibition resulted in increased expression of these factors, associated with reduction in activated NFκB, which likely accounted for the anti-inflammatory phenotype observed in vitro and in vivo after miR-92a blockade. KLF4 is involved in the regulation of endothelial inflammation through blockade of NFκB pathway activation, 25 and KLF2 is known to be protective and modulated by flow in endothelial cells. 16, 39 Moreover, deficiency in KLF2 augments experimental atherosclerosis. 40 More recently, it has been established that endothelial KLF4 protects against atherosclerosis. 41 In addition, we identified SOCS5 as a novel miR-92a target that is involved in the regulation of endothelial inflammation. SOCSs are key regulators of cytokine-induced responses in hematopoietic as well as nonhematopoietic cells. The specific functions of SOCS5 have not yet been determined. Recently, Zhuang et al 42 reported that reduced SOCS5 levels in endothelial cells led to activation of JAK-STAT pathway. Here, we provide the first evidence that SOCS5 expression is induced by shear stress and confers anti-inflammatory properties to endothelial cells.
In the present study, we also demonstrate that miR-92a is expressed in human atherosclerotic lesions and differentially expressed as a function of SS. Preferential expression in downstream parts of human carotid lesions that are subjected to low shear stress is in agreement with our in vitro and in vivo data.
miR-92a expression is controlled by a large variety of transcription factors including STAT3. 28 Our in vitro and in vivo studies unveil a critical role for STAT3 in regulating miR-92a expression, which is in agreement with a recent report showing that STAT3 upregulates miR-92a in lung cancer cells. 43 In conclusion, we report here for the first time that miR-92a is a proatherogenic miR, which specifically promotes endothelial dysfunction and inflammation in a flow-dependent manner. Proatherogenic oxLDL activate miR-92a expression only in atheroprone low SS areas. High SS protects endothelial cells from elevated miR-92a expression but, more importantly, it hampers its induction by oxLDL. Hence, blockade of miR-92a seems as a novel therapeutic strategy to protect against hypercholesterolemia-induced endothelial dysfunction and atherosclerosis development. 
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